Alternatives to Animal Testing Software in 2026: 8 Tools Compared

The OECD QSAR Toolbox is the standard free starting point for in silico toxicology. It groups chemicals with similar structures, finds analogues with known data, and supports read-across predictions for endpoints such as skin sensitisation and mutagenicity. Regulators and industry teams use it widely, which helps when you need a method others recognise.

It is not a push-button tool. Good predictions need careful analogue selection, an understanding of the endpoint, and documentation of why the analogues fit. Data gaps and weak analogues will weaken any prediction, so expert review is essential. For a team starting in non-animal methods, the Toolbox gives you a credible, free foundation.

Derek Nexus, from Lhasa Limited, predicts toxicity by matching chemical structures against expert-written rules, called structural alerts. When it flags a compound, it explains the alert and the evidence behind it, which helps toxicologists judge whether the flag matters for their specific compound. That transparency is why many regulatory teams trust it alongside other tools.

Alerts are a starting point, not a verdict. A flagged structure may still be safe in context, and an unflagged structure is not proof of safety. Licence pricing is quote-based, so budgeting needs a vendor conversation. For teams that need defensible, explainable toxicity screening, Derek Nexus is a leading choice.

GastroPlus, from Simulations Plus, models how a drug is absorbed after oral dosing and how it moves through the body over time. By testing dosing and formulation options in silico, teams can narrow down candidates and study designs before any animal work, and in some cases reduce or avoid animal studies for specific questions. That focus on human prediction is central to modern drug development.

Model quality depends on input data. Poor solubility, permeability, or metabolism data will produce weak predictions, so teams need solid lab data to feed the model. The licence is also a significant investment. For oral drug teams that want to predict human exposure early, GastroPlus is one of the most established tools available.

Simcyp, from Certara, builds virtual populations and simulates how drugs behave in different groups, including children, elderly people, and people with organ impairment. That ability to test dosing in groups that are hard to study directly is a key reason PBPK modelling reduces reliance on animal data. Virtual trials let teams explore dosing, interactions, and variability before clinical work.

Simcyp is a specialist tool. Building and qualifying a model takes training, and the licence reflects its enterprise focus. Small teams may start with simpler tools and move to Simcyp when a regulatory submission needs its depth. For PBPK work at scale, it is a benchmark product.

ADMET Predictor, also from Simulations Plus, estimates absorption, distribution, metabolism, excretion, and toxicity properties directly from a chemical structure. That speed lets teams screen large libraries early, drop risky compounds sooner, and focus lab work on the most promising candidates. Metabolism prediction adds context on how a compound may break down in the body.

Screening predictions are not a substitute for lab or regulatory data, and they work best as a triage step. A flagged compound may still prove safe, and a clean prediction does not guarantee safety. Used early, with expert review, ADMET Predictor can cut wasted synthesis and animal work by focusing effort where it matters.

DILIsym models drug-induced liver injury using systems biology, simulating how a compound and its metabolites interact with liver cells over time. That mechanistic view helps teams understand why a liver signal appears, whether it is likely to progress, and what dose range carries risk. For liver safety, that insight goes beyond a simple toxicity flag.

It is a focused tool, not a general toxicity screen, and it needs detailed input data to run well. Teams without a liver safety question will get little value from it. For drug teams where liver injury is a key risk, DILIsym is a specialised, well-regarded option.

The Toxicity Estimation Software Tool, known as TEST, is a free QSAR tool from the US Environmental Protection Agency. It estimates toxicity for endpoints such as acute toxicity, mutagenicity, and developmental toxicity from chemical structure, using several QSAR methods. That makes it a useful screening and teaching tool, especially for teams with no budget for commercial software.

TEST predictions are screening-level and should not be treated as regulatory proof on their own. The interface is basic, and model coverage varies by chemical class. Pair TEST with the OECD QSAR Toolbox and expert review for a stronger free workflow, and confirm regulatory acceptance for your specific endpoint before relying on it.

VEGA, from the VEGA Hub, offers a collection of free QSAR models for toxicity, ecotoxicity, and physicochemical properties. Each model includes an applicability domain check, which tells you whether your compound sits inside the chemical space the model was built for. That check is important, since predictions outside that space are far less reliable.

Model quality differs across endpoints, and some models are stronger than others, so you need to pick models with care and document your choices. VEGA is best as part of a weight-of-evidence approach, alongside other tools and in vitro data. For a free, broad screening platform, it is a useful addition to any non-animal toolkit.